Gradient Investments LLC Increases Position in Danaher Co. (NYSE:DHR)

Gradient Investments LLC increased its stake in Danaher Co. (NYSE:DHR) by 8.7% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 934 shares of the conglomerate’s stock after purchasing an additional 75 shares during the quarter. Gradient Investments LLC’s holdings in Danaher were worth $233,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Tsfg LLC increased its holdings in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares in the last quarter. Cape Investment Advisory Inc. purchased a new position in Danaher during the 4th quarter valued at about $25,000. Redmont Wealth Advisors LLC purchased a new position in Danaher during the 1st quarter valued at about $30,000. Wetzel Investment Advisors Inc. purchased a new position in Danaher during the 4th quarter valued at about $29,000. Finally, Rakuten Securities Inc. purchased a new position in Danaher during the 4th quarter valued at about $36,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 0.0 %

DHR stock traded down $0.01 during midday trading on Friday, reaching $269.32. 1,746,456 shares of the company’s stock traded hands, compared to its average volume of 2,862,712. The company has a market capitalization of $199.48 billion, a P/E ratio of 45.65, a PEG ratio of 4.62 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The business has a 50-day moving average price of $257.69 and a two-hundred day moving average price of $253.45.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the company posted $2.05 earnings per share. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. Equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Insider Transactions at Danaher

In related news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,707 shares of company stock valued at $10,786,944. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of recent research reports. Robert W. Baird lifted their price target on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. The Goldman Sachs Group lifted their price target on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. SVB Leerink lifted their price target on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Citigroup lifted their price target on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Finally, Evercore ISI lowered their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $276.88.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.